Back Hepatitis C

Hepatitis C

Milk Thistle Drug May Help Control HCV Replication after Liver Transplant

Silibinin, a medication derived from the milk thistle plant, lowered hepatitis C virus (HCV) levels in patients awaiting liver transplantation in a pilot study, which may help reduce the risk of HCV recurrence in the new liver, Spanish researchers reported in the March 2013 Journal of Hepatology.


NS5A Inhibitor Daclatasvir Has Dual Mode of Action Against Hepatitis C Virus

The promising investigational hepatitis C virus (HCV) NS5A inhibitor daclatasvir targets 2 steps of the viral replication process, enabling very rapid HCV RNA reduction, according to a mathematical model described in the February 19, 2013, advance edition of Proceedings of the National Academy of Sciences.


Hepatitis C Re-treatment with Interferon Monotherapy Provides Little Benefit

Long-term re-treatment with pegylated interferon monotherapy offers little or no clinical benefit -- even though it may suppress hepatitis C virus (HCV) levels and improve liver fibrosis -- but it can cause adverse events and may be associated with higher mortality, according to a systematic review from the Cochrane Library.


Liver Cancer Increasing among People with HIV/HCV Coinfection

Hepatocellular carcinoma (HCC) is a growing problem among HIV positive people coinfected with hepatitis C virus (HCV) in Spain, and it is often diagnosed at a late stage when it is difficult to treat, researchers reported in the January 1, 2013, issue of Clinical Infectious Diseases.


Sofosbuvir Combos Match or Beat Standard Hepatitis C Therapy For All Genotypes


The experimental hepatitis C polymerase inhibitor sofosbuvir in an all-oral regimen with ribavirin worked as well as interferon-based therapy for previously untreated people with HCV genotypes 2 or 3, while adding sofosbuvir to pegylated interferon/ribavirin increased cure rates for those with more difficult-to-treat genotypes, Gilead Sciences announced this week.

Updated Boceprevir (Victrelis) Label Adds Data on Prior Null Responders

The U.S. Food and Drug Administration (FDA) announced this week that the product label information for the hepatitis C virus (HCV) protease inhibitor boceprevir (brand name Victrelis) has been updated to include data on treatment of prior null responders.


TAG Releases Updated Guide to Hepatitis C Clinical Trials

The Treatment Action Group (TAG) has produced an updated edition of its guide for people considering participating in clinical trials of new therapies for hepatitis C. Written by Matt Sharp and Tracy Swan, the revised Guide to Clinical Trials for People with Hepatitis C provides an overview of the drug development process, along with information about specific types of HCV treatment.alt

HCV Polymerase Inhibitor Mericitabine Boosts Interferon/Ribavirin Cure Rate

A 24-week response-guided triple regimen consisting of Roche's NS5B polymerase inhibitor mericitabine plus pegylated interferon and ribavirin produced a greater likelihood of sustained viral suppression than a 48-week course of pegylated interferon/ribavirin alone, according to a report in the January 28, 2013, online advance edition of Hepatology.


Tattoos Are Associated with Hepatitis C Virus Infection in the Absence of Other Risk Factors

Individuals with chronic hepatitis C virus (HCV) infection in New York City were about 5 times more likely to have a tattoo than people without HCV, even after traditional risk factors such as injection drug use were taken into account, researchers reported in the January 12, 2013, advance online edition of Hepatology.alt